In Situ Crosslinked Hydrogel Depot for Sustained Antibody Release Improves Immune Checkpoint Blockade Cancer Immunotherapy
Open Access
- 12 February 2021
- journal article
- research article
- Published by MDPI AG in Nanomaterials
- Vol. 11 (2) , 471
Abstract
The therapeutic inhibition of immune checkpoints, including cytotoxic T lymphocyte-associated protein (CTLA)-4 and programmed cell death 1 (PD-1), through the use of function blocking antibodies can confer improved clinical outcomes by invigorating CD8+ T cell-mediated anticancer immunity. However, low rates of patient responses and the high rate of immune-related adverse events remain significant challenges to broadening the benefit of this therapeutic class, termed immune checkpoint blockade (ICB). To overcome these significant limitations, controlled delivery and release strategies offer unique advantages relevant to this therapeutic class, which is typically administered systemically (e.g., intravenously), but more recently, has been shown to be highly efficacious using locoregional routes of administration. As such, in this paper, we describe an in situ crosslinked hydrogel for the sustained release of antibodies blocking CTLA-4 and PD-1 signaling from a locoregional injection proximal to the tumor site. This formulation results in efficient and durable anticancer effects with a reduced systemic toxicity compared to the bolus delivery of free antibody using an equivalent injection route. This formulation and strategy thus represent an approach for achieving the efficient and safe delivery of antibodies for ICB cancer immunotherapy.Keywords
Funding Information
- U.S. Department of War (CA150523)
- National Institutes of Health (S10OD016264, T32EB021962)
This publication has 36 references indexed in Scilit:
- Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 AntibodyNano Letters, 2016
- Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell ResponsesImmunity, 2015
- Enhanced tumor-targeted gene delivery by bioreducible polyethylenimine tethering EGFR divalent ligandsBiomaterials Science, 2015
- Subcutaneous Administration of Monoclonal Antibodies in OncologyGeburtshilfe und Frauenheilkunde, 2014
- Intratumoral Immunization: A New Paradigm for Cancer TherapyClinical Cancer Research, 2014
- Development of a Subcutaneous Formulation for Trastuzumab - Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing RegimenArzneimittelforschung, 2012
- Subcutaneous Absorption of Monoclonal Antibodies: Role of Dose, Site of Injection, and Injection Volume on Rituximab Pharmacokinetics in RatsPharmaceutical Research, 2011
- NONOates–Polyethylenimine Hydrogel for Controlled Nitric Oxide Release and Cell Proliferation ModulationBioconjugate Chemistry, 2011
- In situ gelling stimuli-sensitive block copolymer hydrogels for drug deliveryJournal of Controlled Release, 2008
- CTLA-4: new insights into its biological function and use in tumor immunotherapyNature Immunology, 2002